COMPANY LIST

Business Expansion
on Kobe's Port Island

366

companies

as of November 30, 2019

KOBE Life Science
Cluster Company List

Companies listed in this brochure are participants of the Kobe Medical Industry Development Project and operating on Kobe Port Island. Companies are divided into each categories by their major business field on Kobe Port Island. In the case they have other business fields, it is shown in the miner field.

Search by Company name & Keyword

  • Business
  • Location
  • Initial

Business sector search resultsProduction of drugs and quasi drugs

110of Results 37

Re-search in Business sector

Major field

Miner field

Company name

Business outline

Regenerative medicine
Production of drugs and quasi drugs
Aeras Bio Inc.
Development of dental pulp stem cell technologies and marketing of oral care products
Production of drugs and quasi drugs
Medical equipment Cosmetic
Bee Brand Medico Dental Co., Ltd.
R&D of dental medication, quasi drugs, and dental equipments
Cosmetic
Production of drugs and quasi drugs
Bonanza Co.,Ltd.
R&D, production and sales, OEM of cosmetics and dietary supplements
Production equipment
Regenerative medicine Production of drugs and quasi drugs
DAIKIN APPLIED SYSTEMS CO.,LTD
Total engineering from construction and maintenance of factories and CPC in the field of drugs and cell culturing
Production of drugs and quasi drugs
Enomoto Pharmaceutical Co.,Ltd
Wholesale of generic drugs.
Genomics
Contract research Production of drugs and quasi drugs
Evec, Inc.
Cloning the particular antibody from human peripheral B-cells for development of clinical drug, diagnostic reagent, and for seeking biomarkers.
Distributer
Regenerative medicine Production of drugs and quasi drugs
FUJI CHEMICALS LTD.
Sales of reagents and devices related to physics and chemistry
Production of drugs and quasi drugs
Drug discovery Chemical synthesis
Hamari Chemicals Ltd.
Development of APIs(active pharmaceutical ingredients) and intermediates
Cosmetic
Material and Chemical products Production of drugs and quasi drugs
HONDO INNOVATION CENTER CO.,LTD.
research and development such as cosmetic, quasi drug, and health food
CRO
Regenerative medicine Production of drugs and quasi drugs
IQVIA Japan Group
Regulatory consultation and clinical development service for medical device, regenerative medicine/pharmaceutical product
  1. 1
  2. 2
  3. 3
  4. 4
  5. >

Location search results

110of Results 37

Re-search in Location

Major field

Miner field

Company name

Business outline

Regenerative medicine
Production of drugs and quasi drugs
Aeras Bio Inc.
Development of dental pulp stem cell technologies and marketing of oral care products
Production of drugs and quasi drugs
Medical equipment Cosmetic
Bee Brand Medico Dental Co., Ltd.
R&D of dental medication, quasi drugs, and dental equipments
Cosmetic
Production of drugs and quasi drugs
Bonanza Co.,Ltd.
R&D, production and sales, OEM of cosmetics and dietary supplements
Production equipment
Regenerative medicine Production of drugs and quasi drugs
DAIKIN APPLIED SYSTEMS CO.,LTD
Total engineering from construction and maintenance of factories and CPC in the field of drugs and cell culturing
Production of drugs and quasi drugs
Enomoto Pharmaceutical Co.,Ltd
Wholesale of generic drugs.
Genomics
Contract research Production of drugs and quasi drugs
Evec, Inc.
Cloning the particular antibody from human peripheral B-cells for development of clinical drug, diagnostic reagent, and for seeking biomarkers.
Distributer
Regenerative medicine Production of drugs and quasi drugs
FUJI CHEMICALS LTD.
Sales of reagents and devices related to physics and chemistry
Production of drugs and quasi drugs
Drug discovery Chemical synthesis
Hamari Chemicals Ltd.
Development of APIs(active pharmaceutical ingredients) and intermediates
Cosmetic
Material and Chemical products Production of drugs and quasi drugs
HONDO INNOVATION CENTER CO.,LTD.
research and development such as cosmetic, quasi drug, and health food
CRO
Regenerative medicine Production of drugs and quasi drugs
IQVIA Japan Group
Regulatory consultation and clinical development service for medical device, regenerative medicine/pharmaceutical product
  1. 1
  2. 2
  3. 3
  4. 4
  5. >

You can select the initial.

Initial search results

110of Results 37

Re-search in Initial

Major field

Miner field

Company name

Business outline

Regenerative medicine
Production of drugs and quasi drugs
Aeras Bio Inc.
Development of dental pulp stem cell technologies and marketing of oral care products
Production of drugs and quasi drugs
Medical equipment Cosmetic
Bee Brand Medico Dental Co., Ltd.
R&D of dental medication, quasi drugs, and dental equipments
Cosmetic
Production of drugs and quasi drugs
Bonanza Co.,Ltd.
R&D, production and sales, OEM of cosmetics and dietary supplements
Production equipment
Regenerative medicine Production of drugs and quasi drugs
DAIKIN APPLIED SYSTEMS CO.,LTD
Total engineering from construction and maintenance of factories and CPC in the field of drugs and cell culturing
Production of drugs and quasi drugs
Enomoto Pharmaceutical Co.,Ltd
Wholesale of generic drugs.
Genomics
Contract research Production of drugs and quasi drugs
Evec, Inc.
Cloning the particular antibody from human peripheral B-cells for development of clinical drug, diagnostic reagent, and for seeking biomarkers.
Distributer
Regenerative medicine Production of drugs and quasi drugs
FUJI CHEMICALS LTD.
Sales of reagents and devices related to physics and chemistry
Production of drugs and quasi drugs
Drug discovery Chemical synthesis
Hamari Chemicals Ltd.
Development of APIs(active pharmaceutical ingredients) and intermediates
Cosmetic
Material and Chemical products Production of drugs and quasi drugs
HONDO INNOVATION CENTER CO.,LTD.
research and development such as cosmetic, quasi drug, and health food
CRO
Regenerative medicine Production of drugs and quasi drugs
IQVIA Japan Group
Regulatory consultation and clinical development service for medical device, regenerative medicine/pharmaceutical product
  1. 1
  2. 2
  3. 3
  4. 4
  5. >

Aeras Bio Inc.

Major field:Regenerative medicine

Miner field:Production of drugs and quasi drugs

Development of dental pulp stem cell technologies and marketing of oral care products

Overview

As a subsidiary of Air Water Group that has expanded its business from industrial gas to medical and dental related field. Aeras Bio was founded to promote oral care business and application of dental pulp stem cell technology.

Product / Service / PR

    In recent years oral health has received more attention for its link to body health. Above all, one of the key to prolong healthy lifespan is to keep your own tooth as long as possible. Aeras Bio is establishing a new therapy for treating severe cavities and pulpitis. Dental pulp regenerative therapy revives dental pulp by taking dental pulp stem cell from unwanted tooth in orthodontic treatment or wisdom tooth, then transplant the stem cell to tooth after pulp extraction (root canal), subsequently regenerate the dental pulp. In addition to clinical research in pulp regeneration and enamel regeneration, Aeras Bio is concurrently working on cell extraction, cell culture, preservation and transportation of dental pulp stem cell from unwanted tooth.
Address: 1-3-1, Minatojima-minamimachi, Chuo-ku, Kobe, 650-0047 JAPAN  (Contact Person Morita Yuko)
TEL: +81-78-303-0031 FAX: +81-78-303-0031
Web site: https://aerasbio.cihp2.jp/ E-mail: info-aerasbio-h@awi.co.jp

Bee Brand Medico Dental Co., Ltd.

Major field:Production of drugs and quasi drugs

Miner field:Medical equipment

Miner field:Cosmetic

R&D of dental medication, quasi drugs, and dental equipments

Bonanza Co.,Ltd.

Major field:Cosmetic

Miner field:Production of drugs and quasi drugs

R&D, production and sales, OEM of cosmetics and dietary supplements

DAIKIN APPLIED SYSTEMS CO.,LTD

Major field:Production equipment

Miner field:Regenerative medicine

Miner field:Production of drugs and quasi drugs

Total engineering from construction and maintenance of factories and CPC in the field of drugs and cell culturing

Enomoto Pharmaceutical Co.,Ltd

Major field:Production of drugs and quasi drugs

Wholesale of generic drugs.

Overview

Wholesale of medicinal drugs

Product / Service / PR

    We are selling Japanese government-approved medical drugs to hospitals and pharmacies.
Address: 6-5-5 Minatojima-Minami, Chuo, Kobe, Hyogo 564-0044, JAPAN  (Contact Person Masahiro Enomoto, M.D., Ph.D.)
TEL: +81-6-6385-1401 FAX: +81-6-6330-0465
Web site: http://www.enomoto-yakuhin.co.jp/index.html E-mail: masahiro@enomoto-yakuhin.co.jp

Evec, Inc.

Major field:Genomics

Miner field:Contract research

Miner field:Production of drugs and quasi drugs

Cloning the particular antibody from human peripheral B-cells for development of clinical drug, diagnostic reagent, and for seeking biomarkers.

Overview

Evec, Inc. specializes in the discovery and development of fully human antibody from human peripheral blood B cells. The sensitization process is not needed for our business. According to human phenomena, our products will be high-affinity and also low-immunogenicity.
We have now discovered the visualizing method to detect autoantibodies from individual donor. This might be strong tool for developing diagnostic instrument, next clinical target and biomarkers.

Product / Service / PR

    ・Cloning antibody gene from hybridoma, identification and purification
    ・Class switch of antibody, chimerization and humanization
    ・Antibody generation from particular donors
    ・Potential Evaluation to isolate antibody against particular antigen using our secretome library system
    ・Generation of fully human antibody from peripheral B-cells
    ・Detection of auto-antibody properties from particular donors
    ・Provide the big data of auto-antibody against healthy donors, patients and any kinds of cohorts (Inquiry).
Address: KIBC404, 5-5-2, Minatojima Minamimachi, Chuo-ku, Kobe  (Contact Person Takashi Torashima)
TEL: 011-807-7235 FAX: 011-807-7245
Web site: https://www.evec.jp/ E-mail: support@evec.jp

FUJI CHEMICALS LTD.

Major field:Distributer

Miner field:Regenerative medicine

Miner field:Production of drugs and quasi drugs

Sales of reagents and devices related to physics and chemistry

Hamari Chemicals Ltd.

Major field:Production of drugs and quasi drugs

Miner field:Drug discovery

Miner field:Chemical synthesis

Development of APIs(active pharmaceutical ingredients) and intermediates

Overview

The Hamari Group is composed of three manufacture sites in Japan (Osaka; Yonezawa, Yamagata; Chitose, Hokkaido), two research centers in Japan (Osaka; Kobe) and one U.S. research center (San Diego, California). Hamari Chemicals, Ltd. (Osaka site) is the head office and nexus of project development. Yonezawa Hamari Chemicals, Ltd. is a dedicated manufacture site for large-scale commercial ingredients for both domestic and international markets (e.g. Europe, U.S., etc.) supporting strict international cGMP Guidelines. Chitose Hamari Chemicals, Ltd. is a designated manufacture site for medium-scale ingredients and highly-potent ingredients including small-scale peptides.
Since 2015, Hamari is licensed to manufacture and market pharmaceutical finished dosage forms in Japan. In addition to pharmaceutical products, Hamari, as a manufacturer of health dietary and cosmetics ingredients, will in the near future expand its business to market health dietary food finished products. Chitose Hamari has become the dedicated facility for food extract including fruit juices.

Product / Service / PR

    Hamari has over seventy years’ practical experience in commercial-scale manufacture of active pharmaceutical ingredients and their intermediates using over sixty different types of reactions. Hamari has extended its expertise to tailor-made unnatural amino acid synthesis and asymmetric transfer hydrogenation reactions to manufacture chiral and enantiomeric compounds. Very recently, Hamari’s peptide synthesis capability has expanded from manufacture-scale conventional liquid-phase peptide synthesis to manufacture-scale solid-phase peptide synthesis with construction and installation of dedicated peptide equipment at Chitose Hamari. Moreover, rare or unnatural amino acids that are essential components in difficult-to-synthesize peptides can now be manufactured at commercial scale using Hamari’s patented ligand-based manufacture techniques. In the near future, Hamari commercial manufacture process will cover the full range of protein synthesis from the manufacture of rare or unnatural amino acids, assembly of rare or unnatural long-chained peptides from these amino acids, and eventually, assembly of these peptides for protein folding and expression.
Address: 6F, Kitahama-Matsuoka Bldg., 2-1-26 Kitahama,Chuo-ku, Osaka, 540-0041, Japan  (Contact Person Jeffrey T. Nguyen, PhD)
TEL: +81-6-6205-7755 FAX: +81-6-6205-7222
Web site: https://www.hamarichemicals.com/ E-mail: ask@hamari.co.jp

HONDO INNOVATION CENTER CO.,LTD.

Major field:Cosmetic

Miner field:Material and Chemical products

Miner field:Production of drugs and quasi drugs

research and development such as cosmetic, quasi drug, and health food

IQVIA Japan Group

Major field:CRO

Miner field:Regenerative medicine

Miner field:Production of drugs and quasi drugs

Regulatory consultation and clinical development service for medical device, regenerative medicine/pharmaceutical product

Overview

In April 2018, healthcare consulting firm IMS Health together with the CRO / CSO firm Quintiles Japan, combined to form the IQVIA Japan Group, with a corporate name change and rebrand. IQVIA a world leading company, with over 55,000 employees in more than 100 countries, offering information, innovative technology, and clinical trial services, utilizing data and science to the help the life science industry bring better solutions to patients.

Product / Service / PR

    [IQVIA Services Japan K. K.]
    CRO (Contract Research Organization): Clinical development; Safety data management; Post-marketing surveillance
    CSO (Contract Sales Organization): Medical device sales & marketing support; Healthcare institutions management support
    [IQVIA Solutions Japan K. K.]
    Consulting services and evidence building based on pharmaceutical market data・Real World Data analysis; Commercial, management and business strategy support (technology and consulting) for the life sciences industry.
Address: 4-10-18 Takanawa, Minato-ku, Tokyo,108-0074 Japan  (Contact Person Yoshihiro Ishikawa)
TEL: +813-6894-5420 FAX: +813-6894-5411
Web site: http://www.iqvia.co.jp E-mail: Yoshihiro.Ishikawa@iqvia.com